And welcome to the Vivos Therapeutics First Quarter 2025 Earnings Call. At this time, participants are in a listen-only mode. A question-and-answer session will follow management's remarks. This ...

Lantern Pharma Inc. ( NASDAQ: LTRN) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Panna Sharma - President & CEO David Margrave - CFO ...

Lantern's proprietary RADR ® platform has grown during Q1 2025 to approximately 200 billion oncology-focused data points across multiple sources (proprietary, collaborative and public) of oncology, ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm ...

Avammune Therapeutics has raised $12 Mn as a part of its Series A funding round co-led by Capital 2B, Shastra VC and Kotak ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Greetings, and welcome to TG Therapeutics First Quarter Conference ...